Current Edition

Bluebird

With the pricing situation ‘untenable’ in Europe, Bluebird will wind down its operations in the ‘broken’ market

Unable to reach a consensus with authorities in Europe around fair gene therapy pricing, bluebird bio will “wind down” its operations there to focus on …

Continue Reading →